bloomberg data, page-57

Actually Boreham he gives it a SELL at 60cents.
i can see where he is coming from as the multiples of EPS based on current extrapolated and guessed future income indicate a value of 60c.

What he omitted to consider is the short term anticipated rapid increase in EPS due to expanded market of Fonda due to serious discounting as put forward by DRR and future European income which has to be worth something.

The oncology side is currently worth zilch as we all know.

All in all,ACL has upheld its status as a serial underperformer for us long term holders.